Description
Archimed Capital is a digital asset investment firm, established in 2023 as the successor to Decentral Park Capital (launched 2017). The firm applies a thematic, research-driven approach to investing in cryptoassets, run by a team describing themselves as tech founders, builders, crypto-native investors, and researchers. Archimed operates two complementary products: Liquid Alpha, a highly concentrated, high-conviction liquid token fund built on bottom-up fundamental research into undervalued tokens with genuine value capture; and Native Yield, a zero-leverage, fully on-chain yield strategy that compounds BTC, ETH, SOL and stablecoins through staking, restaking, lending, and market-neutral liquidity provisioning. The firm has backed numerous crypto projects across infrastructure, DeFi, privacy/ZK, and Layer-1 ecosystems (e.g., EigenLayer, Maple, Euler, Kamino, Frax, Storj) via both venture and liquid token investments dating back to 2014. Archimed publishes weekly market commentary ("The Insider") and thematic research via Substack, and serves qualified/accredited investors through an investor portal offering fund documents, NAV reporting, and capital account statements. The legal entity, Archimed Investments Ltd, is based in Seychelles.